The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE:VRX), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade was largely positive, with 80 percent of Vetr user ratings bullish.
Share price In Valeant is back on the uptrend after dipping below $17 earlier in the week after hitting a four-month high of $17.75. The stock closed Thursday's session up, but still below that high at $17.65
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average price target on Valeant is up at $22.46, which is still below the average analyst price target of $24.58. Valeant Pharmaceuticals is a popular stock on Vetr as more than 2 percent of users are holding VRX in their watch-lists.